Amgen Goes Public With Kyprolis Value Data To Supplement ICER Review
This article was originally published in The Pink Sheet Daily
In an unusually public discussion of drug value, the company releases its economic analysis for Kyprolis in advance of an ICER technology assessment of that drug and others for multiple myeloma. Amgen's Martin Zagari says manufacturers must find new ways to present alternative, "rigorous" points of view.
Register for our free email digests: